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phosphate in immune cells – another aspect 
of Fingolimod action relevant for therapeutic 
application
Abstract: FTY720 (Fingolimod; Gilenya®) is an immune-
modulatory prodrug which, after intracellular phospho-
rylation by sphingosine kinase 2 (SphK2) and export, 
mimics effects of the endogenous lipid mediator sphingo-
sine-1-phosphate. Fingolimod has been introduced to treat 
relapsing-remitting multiple sclerosis. However, little has 
been published about the immune cell membrane penetra-
tion and subcellular distribution of FTY720 and FTY720-P. 
Thus, we applied a newly established LC-MS/MS method 
to analyze the subcellular distribution of FTY720 and 
FTY720-P in subcellular compartments of spleen cells of 
wild type, SphK1- and SphK2-deficient mice. These stud-
ies demonstrated that, when normalized to the original 
cell volume and calculated on molar basis, FTY720 and 
FTY720-P dramatically accumulated several hundredfold 
within immune cells reaching micromolar concentra-
tions. The amount and distribution of FTY720 was differ-
entially affected by SphK1- and SphK2-deficiency. On the 
background of recently described relevant intracellular 
FTY720 effects in the nanomolar range and the prolonged 
application in multiple sclerosis, this data showing a sub-
stantial intracellular accumulation of FTY720, has to be 
considered for benefit/risk ratio estimates.
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Introduction
FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-propane-
1,3-diol, Fingolimod, Gilenya®) is an immune-modulatory 
prodrug derived from the natural compound myriocin, 
which is produced by the fungus Isaria sinclairii. It is 
phosphorylated intracellularly by sphingosine kinase 2 
but not sphingosine kinase 1, producing FTY720-phos-
phate (FTY720-P) (Paugh et al., 2003). FTY720-P acts as a 
functional analog of the endogenous ligand sphingosine-
1-phosphate (S1P), which has pleiotropic effects in angio-
genesis (Limaye, 2008), neurological excitability (Bryan 
et al., 2008), cell differentiation (Moriue et al., 2008; Sad-
doughi et  al. 2008; Qin et  al., 2010) and inflammation 
(Huwiler and Pfeilschifter, 2008; Spiegel and Milstien, 
2011). Therefore, in its phosphorylated state, FTY720 has 
been proposed to interfere with functions mediated by S1P 
and is thus investigated in basic research. Moreover, it is 
approved for the treatment of lymphocyte-driven multiple 
sclerosis in men. In order to function via cognate receptors, 
both amphiphilic compounds, S1P and FTY720-P, have to 
leave the cell by an energy-dependent process mediated by 
transporters. Several partly conflicting reports have been 
published regarding the S1P transport mediated by ABC 
transporters, such as ABCA1, ABCC1 and ABCG2 (Liu et al., 
2014; Nishi et al., 2014) as well as for the spinster homolog 
2 (SPNS2) (Hisano et al., 2011; Fukuhara et al., 2012).
Outside the cell S1P can bind to five distinct 
G-protein-coupled receptors and – dependent on the 
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expression profiles of these five S1PRs – elicits cell-type-
specific responses (Blaho and Hla, 2014). FTY720-P exhib-
its nanomolar affinities for all of these apart from S1PR2 
(Mandala et al., 2002). Upon binding of S1P or FTY720-P 
the receptors internalise. This internalisation is prolonged 
upon FTY720-P-binding compared to S1P-binding because 
the receptors are not readily recycled but ubiquitin-
dependently degraded inside the cell to a greater extent, 
reducing the total number of receptors being recycled 
(Brinkmann et  al., 2010; Oo et  al., 2011). Thus, besides 
its agonistic action FTY720 is also a partial functional 
antagonist of S1P. As S1PR1 is essential for the trafficking of 
immune cells such as T and B cells, dendritic cells and mac-
rophages from lymphatic organs into the bloodstream, the 
functional antagonistic property of FTY720-P causes their 
sequestration and ultimately interferes with the migra-
tion of these cells to sites of inflammation (Matloubian 
et  al., 2004; Schwab et  al., 2005, Cinamon et  al., 2008). 
This mechanism is exploited by the recently approved 
FTY720-treatment of multiple sclerosis, which supposedly 
traps autoreactive T cells inside the lymph nodes (Brink-
mann et al., 2010). For the long-term application of FTY720 
during the treatment it is important to reliably measure 
the concentrations of FTY720 and FTY720-P in human 
plasma and especially in the subcellular compartments of 
the target cells. Although the in vivo metabolism of FTY720 
and the extracellular effect of FTY720-P on S1P1,3–5 are well 
understood (Brinkmann et  al., 2010; Oo et  al., 2011), far 
less is known about its distribution at subcellular levels.
In the present study we investigated several aspects 
of cellular handling and metabolism of FTY720 in vitro, 
using LC-MS/MS to quantify FTY720 and FTY720-P. We 
determined the overall intracellular accumulation and the 
subcellular localization of FTY720 and FTY720-P in major 
compartments, and whether this distribution is affected 
by the lack of either SphK1 or SphK2. As might be expected 
from a pharmacological judgement of the Fingolimod 
structure, our data clearly stress the fact that this prodrug 
significantly accumulates inside immune cells. Thereby 
we are directing more attention to recently described 
relevant intracellular targets such as S1P-metabolizing 
enzymes or phospholipases that might contribute to addi-
tional effects of the compound in disease treatment.
Results
To determine how FTY720 and FTY720-P are distributed in 
different cellular compartments of spleen cells and how 
this distribution is affected by the deletion of sphingosine 
kinases, we used wt-C57BL/6, SphK1- and SphK2-deficient 
spleen cells and incubated them with 1 μm FTY720 for 
15 h. We determined FTY720 and FTY720-P in the super-
natant, cytosol, membrane and nuclear fractions, which 
have been separated as stated in the Methods section. Our 
investigations revealed, that the distribution of FTY720 
and FTY720-P was different among the four fractions and 
was, interestingly, not only dependent on the presence of 
SphK2 but also on SphK1. In our first approach determin-
ing the drug concentrations in the respective cellular com-
partment preparations, independent from the intracellular 
and extracellular volume as well as the suspension volume, 
we measured FTY720 amounts highest in the nuclear frac-
tion of wild type cells (54.63±25.70 ng/ml) (Table 1 A). 
FTY720-P was mainly detected in the supernatant 
(55.77±33.57 ng/ml) and the cytosol (54.59±24.70 ng/ml). 
Different from wild type cells, in SphK1-deficient sple-
nocytes we measured both FTY720 (129.64±13.58 ng/ml) 
and FTY720-P (127.75±5.87 ng/ml) at highest levels in the 
cytosol (Table 1B). Cells deficient for SphK2 were unable to 
phosphorylate FTY720 and generate FTY720-P, which con-
sequently led to higher amounts of FTY720 in the super-
natant (75.71±28.27 ng/ml) and the cytosol (172.23±42.99 
ng/ml) (Table 1C). We also normalized the amounts of the 
drugs to the extracellular volume (supernatant) or the sus-
pension volume (subcellular compartments) in order to 
provide total amounts (Table 1). Furthermore, to illustrate 
physiologically relevant concentrations of both drugs, in 
Figure 1 we show levels of FTY720 and FTY720-P normal-
ized to their respective molecular weights. Notably, this 
calculation offered that FTY720 was mainly localized in 
the supernatant from wild type and SphK1-deficient cells 
(Figure 1). Interestingly, the same was true for FTY720-P 
which has been transported out of the cells upon phos-
phorylation. However, FTY720-P was not found in the 
supernatant of SpK2-deficient cells, as FTY720 could not 
be phosphorylated in those cells. Notably, we thus found 
higher extracellular levels of the parental compound.
Nevertheless, Table 1 and Figure 1 imply the overall 
determined compartment distribution of FTY720 and of 
FTY720-P based on the absolute quantities of the com-
pounds determined by LC-MS/MS, normalized to the 
volume of supernatant and volume of cell suspension 
obtained by applying the lipid extraction method and the 
final volumes for the measurement. To obtain the actual 
situation present in a united cells structure, we estimated 
the exact amounts of FTY720 and FTY720-P by evaluating 
the volume of a single cell compared to its extracellular 
space (Figure 2). To calculate the extra- and intracellular 
fractions we confirmed the mean splenocyte volume by 
an intensive literature study. In agreement with our own 
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measurements (data not shown), many reliable investi-
gations measured a median mouse lymphocyte diameter 
close to 7 μm, which equals a volume of spheric cells of 
180 fl (von Andrian and Mackay 2000; Rathmell et  al., 
2001). Lymphocytes comprise the main population in the 
spleen, as erythrocytes are lysed in our cell culture proto-
col, leading to a determination of a volume of 3.6 μl as the 
total cellular volume for all 20 × 106 splenocytes. Notably, 
these calculations offered a completely new insight 
into the real distribution of the compounds. As shown 
in Figure 2, FTY720 and FTY720-P accumulated dra-
matically inside the cells compared to the supernatant. 
In wt splenocytes an extracellular concentration of 
0.08±0.029 μm FTY720 and 0.144±0.087 μm FTY720-P was 
determined (Figure 2A). However, in contrast, we assessed 
a dramatic intracellular increase over the supernatant 
concentration. For FTY720 (87.037±52.579 μm) a 1088-fold 
and for FTY720-P (49.796±27.572 μm) a 346-fold eleva-
tion was evaluated. For the SphK1-deficient spleen cells, 
amounts of 0.064±0.009 μm FTY720 and 0.176±0.019 μm 
FTY720-P were calculated in the supernatant (Figure 2B). 
Conversely, the intracellular concentrations of FTY720 and 
FTY720-P in SphK1-deficient cells were 111.441±16.663 μm 
and 75.262±4.965 μm, implying a 1741- and 428-fold 
Table 1 Extra- and intracellular distribution of FTY720 and FTY720-P in murine splenocytes.
  Fractions   FTY720 (ng/ml)   FTY720 (ng)   FTY720-P (ng/ml)   FTY720-P (ng)
A          
WT   Supernatant   24.53±8.76   122.63±43.78   55.77±33.57   278.83±167.86
  Cytosol   21.17±26.50   10.59±13.25   54.59±24.70   27.30±12.35
  Membrane   31.53±16.53   12.61±6.61   11.96±8.45   4.79±3.38
  Nucleus   54.63±25.70   43.71±20.56   20.19±13.73   16.15±10.98
B          
SphK1-/-   Supernatant   19.42±2.73   97.09±13.64   67.96±7.19   339.79±35.93
  Cytosol   129.64±13.58   64.82±6.79   127.75±5.87   63.88±2.94
  Membrane   2.58±0.63   1.03±0.252   3.26±0.68   1.30±0.27
  Nucleus   20.23±3.85   16.18±3.08   9.66±2.01   7.73±1.60
C          
SphK2-/-   Supernatant   75.71±28.27   378.56±141.36   0   0
  Cytosol   172.23±42.99   86.11±21.49   0   0
  Membrane   23.32±14.70   9.33±5.88   0   0
  Nucleus   38.35±13.45   30.68±10.76   0   0
The obtained FTY720/FTY720-P concentrations from LC-MS/MS measurement are given in ng/ml and in ng, calculated on the basis of the 
volume used for the lipid extraction procedure, for (A) wt-C57BL/6, (B) SphK1-/- and (C) SphK2-/- spleen cells. For each measurement, 20 × 106 
splenocytes were incubated for 15 h with 1 μm FTY720 and the amount of FTY720 and FTY720-P was quantified with LC-MS/MS. Data are 
given as mean±SD from six independent experiments. For statistical analysis two-way ANOVA was used.
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Figure 1 Comparison of FTY720 and FTY720-P amount in different cellular compartments of murine splenocytes.
20 × 106 splenocytes from wt-C57BL/6, SphK1- and SphK2-deficient mice were incubated for 15 h with 1 μm FTY720 and the concentrations of 
FTY720 (A) and FTY720-P (B) were obtained by LC-MS/MS and calculated in nmol on a linear scale. Data are given as mean±SD from n = 6 and 
significant values are indicated as p < 0.001 achieved by two-way ANOVA statistical calculations.
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accumulation inside the cells. As mentioned above, the 
SphK2-deficient splenocytes were not able to phosphoryl-
ate FTY720. Hence, there is a greater intracellular accu-
mulation of FTY720 (164.059±49.6 FTY720 μm), which was 
664-times over the supernatant fraction concentration 
(0.247±0.092 μm) but no detectable amounts of FTY720-P 
where found (Figure 2C).
Discussion
Our newly established LC-MS/MS method for analyzing 
FTY720 and FTY720-P (Ferreirós et  al., 2012) allowed us 
to determine the distribution of FTY720 and FTY720-P in 
murine splenocytes. We distinguished four fractions: (1) 
medium surrounding the cells, (2) cytosol, (3) nucleus and 
(4) the membranous compartments. Because the major 
FTY720 bio-activating enzyme SphK2 is located primarily 
in the nuclear and membranous compartments (Igarashi 
et al., 2003; Hait et al., 2009) we were interested to analyze 
how FTY720 and FTY720-P are distributed not only in wild 
type mice, but also in the splenocytes deficient for SphK2. 
Furthermore, our concern was to determine whether 
the distribution of FTY720 and FTY720-P is affected in 
the absence of the enzyme SphK1, phosphorylating S1P 
extranuclearly.
The present study focuses on a representative mixture 
of immune cells that is typically involved in autoimmune 
diseases and demonstrated a dramatic intracellular molar 
accumulation of FTY720 and FTY720-P (Figure 2). This 
accumulation was calculated in detail, considering the 
molarities and the distribution volumes in different com-
partments, e.g. of the supernatant (5 ml) vs. the spleno-
cytes with a volume of 3.6 μl for 20 × 106 cells. Thus, our 
data imply a prominent intracellular increase of FTY720/
FTY720-P in wild type and SphK1-deficient spleen cells of 
346- to 1741-fold, respectively. In comparison, the highest 
concentration of S1P measured in vivo was only about 1 
μm in the extracellular blood compartment (Skoura and 
Hla, 2009). Our results are strongly supported by the find-
ings of Sensken et  al. (2009) who also demonstrated an 
accumulation of FTY720 in lymphocytes. Our data confirm 
these findings and moreover, show the intracellular dis-
tribution of Fingolimod in different compartments of 
the spleen cells and the influence of S1P metabolizing 
enzymes.
Clearly, FTY720 is uniquely phosphorylated by SphK2 
as confirmed in this study (Table 1C, Figures 1 and 2) and 
described before by Paugh et al. (2003). Furthermore, data 
normalized to the suspension volume and to molecular 
weight of the respective drug revealed that FTY720 was 
localized apart from a big proportion within the super-
natant, mainly in the nucleus of wild type splenocytes 
(Figure 1A). However, in SphK1- and SphK2-deficient sple-
nocytes the highest intracellular levels of FTY720 were 
not detected in the nucleus but in the cytosol. Obviously 
the deficiency of one of the two S1P-generating enzymes 
is responsible for this differential distribution, although 
up to now only SphK2 has been assigned to interact with 
FTY720, performing the phosphorylation. Additionally, in 
SphK2-deficient cells, the total amount of FTY720 meas-
ured was dramatically increased compared to wild type 
cells because the cells were unable to synthesize any 
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Figure 2 Extracellular vs. intracellular molar concentrations of FTY720 and FTY720-P of murine splenocytes in original cell volumes.
From the calculated amounts of FTY720 and FTY720-P of wt-C57BL/6 (A), SphK1- (B) and SphK2- (C) deficient spleen cells measured by 
LC-MS/MS were assessed the total intracellular (in.) and extracellular (ex.) concentrations in μm, taking the original natural cell volume, 
the dilution factor and the extraction volume into account. Data are given as mean±SD from n = 6 and significant values are indicated as 
p < 0.001 achieved by two-way ANOVA statistical calculations.
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FTY720-P. These increased concentrations of FTY720 might 
also contribute to the differential distribution of the com-
pound detected in each of the four fractions (Figure 1). It is 
known from the literature that a deficiency of both sphin-
gosine kinases, leads to embryonic lethality. However, no 
obvious phenotype is known in single knockout mice, 
indicating that apart from specific exceptions (Oskeritzian 
et al., 2008; Price et al., 2013) one enzyme may substitute 
the other (Alemany et  al., 2007). The increased concen-
tration of FTY720-P in the cytosol of the SphK1-deficient 
cells may thus be the result of a compensatory increase of 
SphK2 activity.
Intracellular, endogenous lipids undergo a continu-
ous turnover with an exchange rate of at least 1 μm2 of 
lipid layer in a few seconds (van Meer and de Kroon, 
2011). Nevertheless, lipids like sterols or sphingolipids 
reside at distinct intracellular spaces and are not spread 
randomly throughout the double-layered membranes 
of the cell. Gerrit van Meer and colleagues postulated 
that specific lipid sorting takes place due to a vesicular 
pathway maintained by the Golgi apparatus (Simons and 
van Meer, 1988; Neumann and van Meer, 2008). For the 
endogenous sphingolipid S1P this transportation system, 
and also the export via ABC transporters (Liu et al., 2014; 
Nishi et  al., 2014) and the SPNS2 transporters (Hisano 
et  al., 2011; Fukuhara et  al., 2012), have been repeat-
edly described. With regard to FTY720, there exist only 
a few inconclusive studies investigating its transporta-
tion mechanisms. In T cells, both FTY720 and FTY720-
P enhanced the efflux activity of the ABCB1 transporter 
(Honig et  al., 2003). In contrast, stimulus-mediated 
release of FTY720-P has been described to be inde-
pendent of ABCB1 or ABCC1 in platelets (Anada et  al., 
2007). Another study reasoned that FTY720-P is trans-
ported out of mouse brain and spinal cord endothelial 
cells by ABCC1 (Mrp1) (Cartwright et al., 2013). Further-
more, FTY720 was implemented to affect the cholesterol 
balance and increased the ABCA1 mRNA and protein 
levels in human primary macrophages (Blom et  al., 
2010). While these conflicting data are not yet resolved 
experimentally, the most likely explanation is a cell type- 
and tissue-specific expression and regulation of sphin-
golipid transport systems. Besides transportation, lipid 
levels are also regulated by their metabolism.
Intracellular S1P is faced continuously towards its 
degrading enzymes, the S1P phosphatases 1/2 as well as 
S1P lyase. However, according to published evidence, 
the S1P lyase is not capable to cleave FTY720-P but is 
rather inhibited by the compound (Bandhuvula et  al., 
2005). This represents another plausible explanation for 
a constantly high intracellular Fingolimod concentration 
in respective sub-compartments. Lim et al. (2011) deter-
mined a Km value for SphK2 to phosphorylate FTY720 
of about 5–10 μm. Therefore, it seems quite reasonable 
to assume that these high concentrations of FTY720-
P are also reached in humans receiving Fingolimod for 
the treatment of MS. Otherwise the required levels of 
the phosphorylated Fingolimod compound would not 
be available for the S1P receptor targets. As mentioned 
above, to achieve a therapeutic sequestration effect in 
disease such as relapsing-remitting MS, it is crucial for 
FTY720-P to bind to the S1PRs and to abolish the migra-
tion of autoreactive T cells to the blood. It is however very 
possible that the significant intracellular accumulation 
of this substance described by our data, may explain 
part of the surprising therapeutic efficacy of even low 
dosage levels in MS as compared to its formerly applied 
dosage in transplantation (Kappos et  al., 2010). There-
fore, by interpreting our findings in a positive direction, 
Fingolimod may affect immune cell-relevant intracellu-
lar targets, such as phospholipase A2 (PLA2) and protein 
phosphatase 2A (PP2A) (Payne et  al., 2007; Saddoughi 
et  al., 2013; Arlt et  al., 2014). These results have to be 
further confirmed by an in vivo model, e.g. by intra peri-
toneal or oral treatment of mice with FTY720, isolating 
spleen cells followed by detection of the two compounds 
via LC-MS/MS. Thus, above the S1P receptor-dependent 
activities of Fingolimod, the prominent intracellular 
accumulation of FTY720 shown in our investigation 
may point to additional and relevant molecular targets 
not considered in MS treatment so far. Therefore, these 
findings should be discussed for both, optimization of 
the therapeutic application including a thorough drug 
monitoring in order to avoid unwanted side effects and 
the evaluation of new intracellular drug targets being 
supportive during a long-term treatment of patients with 
autoimmune diseases.
Materials and methods
Materials
Acetonitrile, ethanol and methanol (gradient grade), tetrahydrofuran 
(for HPLC), formic acid (89–91% purity grade) and hydrochloric acid 
(32% purity grade), both for analysis, were purchased from Merck 
(Darmstadt, Germany). Water (LC-MS grade) and dimethyl sulfoxide 
(analytical reagent grade) were obtained from Carl Roth (Karlsruhe, 
Germany) and Fisher Scientific (Schwerte, Germany), respectively.
FTY720 (MW: 307.47 g/mol) and FTY720-P (MW: 387.5 g/mol) 
were purchased from Cayman Chemical (Ann Arbor, MI, USA) as 
well as C17-sphingosine (C17-SPH) and C17-sphingosine-1-phosphate 
(C17-S1P) which were used as internal standards.
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Preparation of splenocytes and fractionation
Female wild type mice (wt-C57BL/6) were purchased from Harlan 
Winkelmann (Borchen, Germany); Female SphK1-deficient (SphK-/-) 
and SphK2-deficient (SphK2-/-) mice, backcrossed to the C57BL/6 
background, were bred at the local animal facility under specific 
pathogen-free conditions (Frankfurt, Germany). Whole spleens 
were dissected from mice, gently homogenized with a glass tissue 
homogenizer (OMNI International, USA), and following ammonium-
chloride-potassium (ACK) buffer mediated erythrolysis cultured in 
Iscove’s medium supplemented with 5% fetal calf serum (FCS) (PAA 
Laboratories, Egelsbach, Germany), 2 mm L-glutamine, 100  IU/ml 
penicillin, 100 μg/ml streptomycin, 1 mm sodium pyruvate, 100 μm 
non-essential amino acids and 50 μm β-mercaptoethanol (all from 
Sigma Aldrich, Deisenhofen, Germany) in an humidified incubator 
(5% CO2 and 37° C).
Splenocytes were seeded at 20 × 106 cells/5  ml in T25 cell cul-
ture flasks (Sigma Aldrich, Deisenhofen, Germany) with serum-free 
Iscove’s medium (PAA Laboratories, Egelsbach, Germany). The cells 
were incubated with 1 μm FTY720 (Cayman Chemical, Ann Arbor, 
MI, USA) for 15 h. The splenocytes were then gently rubber-scraped 
and centrifuged at 4°  C at 300 g. The cell-free supernatants were 
collected (medium samples). The remaining cell pellets were lysed 
with a sonicator (Branson Sonifier 450, Heinemann Labortechnik, 
Schwäbisch Gmünd, Germany) (30 s, 50 W, 10%) in 500 μl proteinase 
inhibitor buffer (PI) (Roche, Basel, Switzerland) and 10 mm HEPES 
(Sigma Aldrich, Deisenhofen, Germany). Subsequent centrifugation 
at 400 g for 10 min at 4° C yielded the nuclear fraction as pellet while 
the supernatant was re-centrifuged at 180 000 g (TLX ultracentrifuge, 
Beckman, Ramsey, USA) for 30 min providing the membrane fraction 
and the cytosolic fraction. The nuclear pellets as well as the mem-
brane fractions were resuspended in PI-buffer and diluted 1:10 before 
lipid extraction to be inside the lower and upper limit of quantifica-
tion for the LC-MS/MS detection process.
Sample extraction and standard preparation
The generated samples were extracted as we have previously described 
(Ferreirós et al., 2012). Briefly, the sample was spiked with the inter-
nal standard solved in methanol (15 ng/ml C17-sphingosine and 10 
ng/ml C17-sphingosine-1-phosphate). For the preparation of a stand-
ard curve for FTY720 and FTY720-P appropriate methanolic working 
solutions were generated (1 mg/ml in methanol). A calibration curve 
from 0.875–175 ng/ml for FTY720 and from 2–400 ng/ml for FTY720-
P was prepared by spiking of the appropriate methanolic working 
solution. Then, deionized water, methanol and the extraction solvent 
(chloroform:methanol:HCl, v/v/v, 83:15:2) were added. After vortexing 
this mixture for 1  min and a subsequent centrifugation at 17 000 g, 
the upper layer was disposed and the organic layer was evaporated at 
45° C under a nitrogen stream. The residue was reconstituted in 50 μl 
methanol and used for injection into the LC-MS/MS system.
LC-MS/MS measurement
FTY720 and FTY720-P were quantified with LC-MS/MS as described 
by us before (Ferreirós et al., 2012). Briefly, 10 μl of the samples were 
injected into the LC-MS/MS system with a flow rate of 0.3 ml/min 
and separated chromatographically, using a Luna C18 (2)  column 
(150 × 2  mm I.D., 5 μm particle size and 100 Å pore size) with a 
C18 guard column (4 × 2  mm I.D.) (Phenomenex, Aschaffenburg, 
 Germany). The LC-MS/MS system consisted of an Agilent 1100 Series 
binary pump (G1312A) and degasser (G1379A) (Waldbronn, Germany) 
with an HTC PAL autosampler (Chromtech, Idstein, Germany). A 
triple quadrupole mass spectrometer 4000 QTRAP equipped with a 
Turbo V IonSpray source operated in positive ESI mode was used for 
detection (AB Sciex, Darmstadt, Germany).
Statistical analysis
The software package of Graph Pad Prism 5.01 (La Jolla, USA) for 
Windows was used for statistical analysis of collected and presented 
data. Data are given as mean±SD from six independent experiments. 
Appropriate two-way ANOVA as the statistical calculation method 
was applied and significant values are indicated as asterisks in 
the figure legends (*/**/*** represent p values of p  ≤  0.05, p  ≤  0.01, 
p  ≤  0.001, respectively).
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